XML 29 R19.htm IDEA: XBRL DOCUMENT

Note Payable

6 Months Ended

Jun. 30, 2022

Note 10. Notes Payable

Notes payable consisted of the following at June 30, 2022 and December 31, 2021 (in thousands):


	June 30,		December 31,
	2022		2021
Principal amount of CRYOPDP note payable	$	1,043	$	1,133
Principal amount of Cell&Co notes payable		432		—
Less: discount on CRYOPDP note payable		(22)		(47)
Total notes payable		1,453		1,086
Less: current portion of notes payable		(1,079)		—
Notes payable – long term	$	374	$	1,086

Interest expense incurred in connection with the notes payable consisted of the following for the three and six months ended June 30, 2022 and 2021 (in thousands):


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2022		2021		2022		2021
Interest expense	$	2	$	—	$	2	$	—
Amortization of debt discount		11		33		21		98
Total interest expense on notes payable	$	13	$	33	$	23	$	98

CRYOPDP Note

In connection with the acquisition of CRYOPDP, the Company assumed an interest free unsecured note payable of €4.0 million

($4.5 million) repayable in two installments. The first installment of €3.0 million ($3.4 million) was paid in December 2021 and the second installment of €1.0 million ($1.1 million) is to be repaid no later than December 31, 2022. A fair market value discount of €0.2 million ($0.3 million) was recorded and is amortized to interest expense using the effective interest method over the term of the note.

Cell&Co Notes

In connection with the acquisition of Cell&Co, the Company assumed two notes payable totaling €0.4 million ($0.4 million) bearing interest rates of 0.6% and 1.06%, respectively, payable quarterly, maturing in July 2027 and June 2030, respectively.

Future note payments as of June 30, 2022 were as follows (in thousands):


Years Ending December 31,	Amount
2022 (excluding the six months ended June 30, 2022)	$	1,072
2023		59
2024		59
2025		60
2026		60
Thereafter		165
Total note maturities		1,475
Debt discount		(22)
Net notes payable carrying value	$	1,453